Basic HTML Version
PROKINETIC BMS IN ACS
remains a practical option for use even in the DES era,
and should be considered especially in patients with
ACS.
References
1. Dussaillant GR, Mintz GS, Pichard AD, et al. Small stent
size and intimal hyperplasia contribute to restenosis: A vol-
umetric intravascular ultrasound analysis. J Am Coll Cardiol
1995;26:720–724.
2. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and
mechanisms of in-stent restenosis. A serial intravascular ultra-
sound study. Circulation 1996;94:1247–1254.
3. Kastrati A, Mehilli J, Dischinger J, et al. Intracoronary stenting
and angiographic results: Strut thickness effect on restenosis
outcome (ISAR-STEREO) trial. Circulation 2001;103:2816–
2821.
4. Pache J, Kastrati J, Mehilli, et al. Intracoronary stenting and an-
giographic results: Strut thickness effect on restenosis outcome
(ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283–
1288.
5. Kveen GL, Doran BP, Judnitch RT (Scimed Life Sys-
tems, Inc.). Helical stent design. United States Patent no.
6488703.12/03/2002.
6. K¨oster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum
contact allergies in patients with coronary in-stent restenosis.
Lancet 2000;356:1895–1897.
7. Tolleson TR, Kristin Newby L, Harrington RA, et al.; SYM-
PHONY and the 2nd SYMPHONY Investigators. Frequency
of stent thrombosis after acute coronary syndromes (from the
SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol
2003;92:330–333.
8. Monnink SH, Van Boven AJ, Peels HO et al. Silicon-carbide
coated coronary stents have low platelet and leukocyte adhesion
during platelet activation. J Investig Med 1999;46:375–381.
9. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, et al.
Real-world eluting-stent comparative Italian retrospective
evaluation study investigators. Incidence, predictors, and out-
comes of coronary dissections left untreated after drug-eluting
stent implantation. Eur Heart J 2006;27:540–546.
10. Laskey WK, Selzer F, Jacobs AK, et al. Williams and NHLBI
Dynamic Registry Investigators. Importance of the postdis-
charge internal in assessing major adverse clinical event rates
following percutaneous coronary intervention. Am J Cardiol
2005;95:1135–1139.
11. Spaulding C, Henry P, Teiger E, et al.; TYPHOON Investiga-
tors. Sirolimus-eluting versus uncoated stents in acute myocar-
dial infarction. N Engl J Med 2006;355:1093–1104.
12. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of ran-
domized trials on drug-eluting stents vs. bare-metal stents
in patients with acute myocardial infarction. Eur Heart J
2007;28:2706–2713.
13. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting
versus uncoated stents in primary percutaneous coronary inter-
vention. New Engl J Med 2006;355:1105–1113.
14. Sanchez-Recalde A, Moreno R, Barreales L, et al. Risk of late-
acquired incomplete stent apposition after drug-eluting stent
versus bare-metal stent. A meta-analysis from 12 randomized
trials. J Invasive Cardiol 2008;20:417–422.
15. Mosseri M, Miller M, Tamari I, et al. The Titanium-NO stent:
Results of a multicenter registry. EuroIntervention 2006;2:192–
196.
16. Karjalainen PP, Ylitalo A, Airaksinen JKE. Titanium and ni-
tride oxide-coated stents and paclitaxel-eluting stents for coro-
nary revascularization in an unselected population. J Invasive
Cardiol 2006;18:462–468.
17. Karjalainen PP, Ylitalo A, Niemela M, et al. Titanium-nitride-
oxide coated stents versus paclitaxel-eluting stents in acute
myocardial infarction: (A 12-month follow-up report from the
TITAX AMI trial). EuroIntervention 2008;4:234–241.
18. Kornowski R, Vaknin-Assa H, Lev E, et al. Clinical results of
drug eluting stents compared to bare metal stents for patients
with ST elevation acute myocardial infarction. Acute Card Care
2008;10:167–172.
19. Menichelli M, Parma A, Pucci E, et al. Randomized trial of
sirolimus-eluting stent versus bare-metal stent in acute myocar-
dial infarction (SESAMI). J Am Coll Cardiol 2007;49:1924–
1930.
20. Fugimoto H, Masuda J, Mitani H, et al. The efficacy of bare
metal stent implantation for patients with acute myocardial
infarction in the drug-eluting stent era. J Cardiol 2008;51:189–
195.
21. Rittersma SZ, de Winter RJ, Koch KT, et al. Impact of strut
thickness on late luminal loss after coronary artery stent place-
ment. Am J Cardiol 2004;93:477–480.
22. Rzany A, Schaldach M. Smart material silicon carbide: Re-
duced activation of cells and protein on a-SIC:H-coated stain-
less steel. Prog Biomed Res 2001;4:182–194.
23. Hamm CW, Hugenholtz PG. TRUST Investigators. Silicon
carbide-coated stents in patients with acute coronary syndrome.
Catheter Cardiovasc Interv 2003;60:375–381.
24. Unverdorben M, Sippel B, Degenhardt R, et al. Comparison
of a silicon carbide-coated stent versus a noncoated stent in
human beings: The Tenax versus Nir Stent Study’s long-term
outcome. Am Heart J 2003;145:e17.
25. Tanajura LF, Abizaid AA, Feres F, et al. Randomized in-
travascular ultrasound comparison between patients that un-
derwent amorphous hydrogenated silicon-carbide coated stent
deployment versus uncoated stents. J AmColl Cardiol 2003;41:
58A.
26. Dahm JB, Willems T, Wolpers HG, et al. Clinical investiga-
tion into the observation that silicon carbide coating on cobalt
chromium stents leads to early differentiating functional en-
dothelial layer, increased safety and DES-like recurrent steno-
sis rates: Results of the PRO-Heal Registry (PRO-Kinetic
enhancing rapid in-stent endothelialisation). EuroIntervention
2009;4:502–508.
27. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of
coronary artery disease and the acute coronary syndromes. N
Engl J Med 1992;326:242–250.
28. Schaefer A, Klein G, Fischer D, et al. Mechanism of coronary
artery restenosis after stenting for acute myocardial infarction.
Am J Cardiol 2004;94:1037–1040.
29. Tanaka A, Kawabayashi T, Nishihiri Y, et al. In-stent resteno-
sis and lesion morphology in patients with acute myocardial
infarction. Am J Cardiol 2003;92:1208–1211.
Vol. 23, No. 4, 2010
Journal of Interventional Cardiology
381